10月 2026
scholar.google.com.pr
グローバルランク
- -
国ランク
- -
カテゴリーランク
- -
Similarwebの推計データを表示しています。
GA4に接続することで、サイトの指標を公開検証することができます。
自社の成功を反映
Google アナリティクスを連携して、ウェブサイトのトラフィックとエンゲージメントの指標を確認します
直帰率
75.55%
ページビュー/訪問
1.89
平均滞在時間
00:00:36
- 当社について
- - -
- 業界
- - -
scholar.google.com.prの競合サイトトップ10
10月 2026のscholar.google.com.prのようなトップ10サイトは、キーワードトラフィック、オーディエンスターゲティング、および市場の重複という観点から、 scholar.google.com.prとの親和性によってランク付けされています。
sciencedirect is the world's leading source for scientific, technical, and medical research. explore journals, books and articles.
- 当社について
- ScienceDirect
直帰率
31.28%
ページビュー/訪問
6.01
平均滞在時間
00:07:55
Explore options for your family: the YouTube Kids app or a parent supervised account for older kids & teens on YouTube, all with built-in protections.
直帰率
23.61%
ページビュー/訪問
11.07
平均滞在時間
00:18:45
類似性スコア
86%academia.edu is a place to share and follow research.
- 当社について
- Academia
直帰率
61.51%
ページビュー/訪問
2.35
平均滞在時間
00:01:41
類似性スコア
80%Access 160+ million publication pages and connect with 25+ million researchers. Join for free and gain visibility by uploading your research.
- 当社について
- ResearchGate
直帰率
46.91%
ページビュー/訪問
3.59
平均滞在時間
00:03:06
We perform a behavioral experiment of karma, a class of mechanisms for repeated resource allocation with attractive fairness and efficiency properties, in theory. Individuals in these mechanisms bid non-tradable credits that flow from resource consumers to yielders. Human subjects recruited on Amazon MTurk are repeatedly and randomly paired to bid karma according to time-varying individual urgency to acquire resources. Treatments varied in the urgency process (frequent moderate versus sporadic high urgency) and the richness of the bidding scheme (binary versus full range). Benchmarked against random allocation, karma achieves an (almost) Pareto improvement, despite subjects deviating from the theoretically optimal Nash bidding policy: maximum improvement is attained by subjects deviating by up to one karma bid unit on average, and positive improvement with deviations of up to 3-4 units. These findings hold across all treatments, among which no significant differences are found, with the exception of the sporadic high urgency process with binary bidding being (weakly) favorable. They offer behaviorally robust lower bounds for karma's expected performance in human populations and guide its future implementation.
- 当社について
- - -
- 業界
- - -
直帰率
39.23%
ページビュー/訪問
3.17
平均滞在時間
00:04:08
類似性スコア
73%indexingmethod_automated - Search Results - PubMed
- 当社について
- - -
- 業界
- - -
グローバルランク
- -
国ランク
- -
カテゴリーランク
- -
直帰率
- -
ページビュー/訪問
- -
平均滞在時間
- -
the world’s largest collection of open access research papers
- 当社について
- - -
- 業界
- - -
直帰率
26.98%
ページビュー/訪問
5.13
平均滞在時間
00:04:27
類似性スコア
65%Abstract Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. Methods In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle–formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. Results A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. Conclusions A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 mont
- 当社について
- - -
- 業界
- - -
直帰率
24.78%
ページビュー/訪問
3.71
平均滞在時間
00:01:07
Learn more about our institutional models for librarians and the benefits for researchers.
- 当社について
- PLOS
直帰率
61.54%
ページビュー/訪問
1.75
平均滞在時間
00:01:42
類似性スコア
61%DOAJ is a unique and extensive index of diverse open access journals from around the world, driven by a growing community, committed to ensuring quality content is freely available online for everyone.
- 当社について
- - -
- 業界
- - -
直帰率
19.35%
ページビュー/訪問
4.43
平均滞在時間
00:01:51
類似性スコア
59%10月 2026におけるscholar.google.com.prの競合サイト上位は、 sciencedirect.com 、 youtube.com 、 academia.edu 、 researchgate.netなどです。
Similarwebの月間訪問数データによると、10月 2026におけるscholar.google.com.prの最大の競合はsciencedirect.comです。次いで親和性が高いサイトはyoutube.com、3位はacademia.eduとなっています。
また、researchgate.netはscholar.google.com.prと4番目に類似したWebサイトとしてランクインし、arxiv.orgが5位に続いています。
トップ10にランクインした他の競合5社は、pubmed.ncbi.nlm.nih.gov、core.ac.uk、scienceopen.com、plos.org、そしてdoaj.orgです。